INT J CANCER 润色咨询

INTERNATIONAL JOURNAL OF CANCER

出版年份：暂无数据 年文章数：9003 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-06-20 ms9000001908456775 来自法国

    请问这个期刊收不收医学图像癌症相关的文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2021-09-04 凶巴巴恰北北怪兽

    7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好

    20

    展开20条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-05-31 ms6000002977722155 来自上海

    今日分享期刊收录方向与稿件要求：
    ​​癌症流行病学​​（如人群队列研究、风险模型）
    ​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）
    ​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）
    ​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）
    ​​创新技术方法​​（单细胞测序、液体活检技术）
    拒稿高风险类型​​
    ​​纯生信分析​​：需搭配实验验证（如WB、IHC）
    ​​Meta分析​​：明确拒收（官网声明）
    ​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观
    ​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性
    需2–3名审稿人
    审稿人专业严谨，意见细致
    投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-04-14 ms8000001554423334 来自美国

    一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-04-27 ms6000002977722155 来自上海

    审稿速度:2.0
    经验分享：2月18日投稿，4月20日接收，总耗时66天。
    审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。
    修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2022-08-22 ms5000001852951271

    偏重的研究方向：leukemia;biomarker
    经验分享：请问under evaluation这种状态，一般要多久呢？

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2022-03-04 1221c8e5m44(暂无昵称)

    审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3
    偏重的研究方向：Meta;epidemiology;Cancer
    经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-02-24 ms9000000156680607 来自重庆

    偏重的研究方向：肿瘤;Environmental Research;Cancer
    经验分享：请问一下under review是内审还是外审啊？

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2024-11-30 ms2000001750570964 来自广西

    审稿速度:3.0
    偏重的研究方向：临床试验
    经验分享：2024..9.5投 9.10under review
    至今还在UR
    都说这个杂志速度快
    看了一圈没一个人比我久的 我都i想催稿了

    8

    展开8条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2270181, encodeId=fcd722e018133, content=请问这个期刊收不收医学图像癌症相关的文章<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa958586989, createdName=ms9000001908456775, createdTime=Fri Jun 20 12:22:41 CST 2025, time=2025-06-20, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收 编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=342, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2267517, encodeId=6ca5226e5175c, content=今日分享期刊收录方向与稿件要求：<br>​​癌症流行病学​​（如人群队列研究、风险模型）<br>​​肿瘤分子机制​​（遗传学、表观遗传学、信号通路）<br>​​肿瘤免疫与微环境​​（免疫治疗响应、微环境调控）<br>​​癌症治疗与预防​​（靶向药物、化疗优化、早期筛查）<br>​​创新技术方法​​（单细胞测序、液体活检技术）<br>拒稿高风险类型​​<br>​​纯生信分析​​：需搭配实验验证（如WB、IHC）<br>​​Meta分析​​：明确拒收（官网声明）<br>​​动物模型图像​​：涉及动物实验需提供伦理批件，且避免展示肿瘤外观<br>​​数据未公开​​：公共数据库（如TCGA/GEO）研究需声明数据可用性<br>需2–3名审稿人<br>审稿人专业严谨，意见细致<br>投稿时建议预留 ​​4–5个月​​ 全程周期（含返修），肿瘤学优质稿件可优先考虑此刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:35:16 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2260388, encodeId=6cf822603880e, content=一篇24年11月10号投的，一篇25年1月2日投的，至今还是Under Review，要不要催一下啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=575b5570191, createdName=ms8000001554423334, createdTime=Mon Apr 14 10:42:58 CST 2025, time=2025-04-14, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=2262560, encodeId=68522262560ef, content=审稿速度:2.0<br>经验分享：2月18日投稿，4月20日接收，总耗时66天。<br>审稿人也很认真负责，第一轮意见通常详细，后续修改要求逐渐简化。<br>修改需要注意的是，逐条回应，并需详细记录每项修改，用高亮或标注明确改动位置，并合理说明未采纳建议的原因。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sun Apr 27 23:32:57 CST 2025, time=2025-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向：leukemia;biomarker<br>经验分享：请问under evaluation这种状态，一般要多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253342, encodeId=eac7225334267, content=偏重的研究方向：肿瘤;Environmental Research;Cancer<br>经验分享：请问一下under review是内审还是外审啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=080c5488805, createdName=ms9000000156680607, createdTime=Mon Feb 24 14:40:28 CST 2025, time=2025-02-24, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0<br>偏重的研究方向：临床试验<br>经验分享：2024..9.5投 9.10under review<br>至今还在UR<br>都说这个杂志速度快<br>看了一圈没一个人比我久的 我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2247783, encodeId=5483224e783dc, content=审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）<br>该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:41:21 CST 2025, time=2025-01-12, status=1, ipAttribution=上海)]
    2025-01-12 ms5000002977722138 来自上海

    审稿周期平均为2个月左右。相对来说，审稿速度还是比较快的（因此大家还是尽量不要频繁催稿）
    该期刊主要发表与癌症相关的研究文章，包括但不限于实验研究、临床研究、综述等。但是需要支付版面费

    0

共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分